This report was first published by Endpoints News. To see the original version, click here
The FDA has approved GSK’s Blenrep as a third-line multiple myeloma drug, overcoming a negative advisory committee vote and clearing the way for a relaunch in the US.
The approval comes after a three-month review delay from the FDA and two negative votes from the agency’s Oncologic Drugs Advisory Committee for the drug as an earlier line of therapy. Blenrep was pulled from the market in 2022 after a failed confirmatory trial.
您已閱讀30%（518字），剩余70%（1229字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。